Use of 5- (2,6-di-morpholin-4-yl-pyrimidin-4-yl) -4-trifluoromethyl-pyridin-2-ylamine for the treatment of non-small cell lung carcinoma with acquired resistance to modulators of the epidermal growth factor receptor (EGFR).

摘要

The use of 5- (2,6-di-morpholin-4-yl-pyrimidin-4-yl) -4-trifluoromethyl-pyridin-2-ylamine, or a pharmaceutically acceptable salt thereof, for the manufacture of a pharmaceutical preparation for the treatment of an EGFR-dependent disease, wherein said disease is resistant to treatment with an EGFR modulator which is selected from the group consisting of gefitinib, erlotinib, lapatinib, cetuximab, nimotuzumab, panitumumab and trastuzumab, and where the disease that depends on EGFR is non-small cell lung carcinoma.